Stock Market
Social Media Influencer Kevin Malone Joins Quantum BioPharma to Combat Naked Short Selling
Quantum BioPharma Ltd. (NASDAQ: QNTM) has made news on X, the social media platform in by appointing Kevin Malone, a prominent social media influencer and wealth management expert, as an advisor to its Board of Directors. Known for his outspoken advocacy against market corruption, particularly naked short selling, Malone brings a unique blend of financial expertise and grassroots influence to the company’s mission.
A New Voice in the Fight Against Stock Manipulation
Kevin Malone, a second-generation financial advisor with over 40 years of family experience in wealth management, has built a reputation for his rigorous research and disciplined investment strategies. Through his firm, Malone Wealth, launched in 2021, he has focused on identifying undervalued assets and navigating complex market conditions. However, it’s his vocal stance against stock manipulation that has garnered him a significant following on social media platforms, where he educates retail investors about market inequities.
Malone’s appointment comes at a pivotal time for Quantum BioPharma, a company dedicated to developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, for multiple sclerosis. The company has also been vocal about its concerns regarding naked short selling—a practice where shares are sold without being borrowed, potentially driving down stock prices unfairly.
Zeeshan Saeed, CEO of Quantum BioPharma, emphasized the significance of Malone’s role: “Kevin’s expertise in naked short squeeze strategies and his passion for fighting market manipulation make him an invaluable addition to our team. His presence strengthens our resolve to protect our shareholders and advance our mission.”
From GameStop to Quantum: Malone’s Mission
Malone’s journey as an advocate began in 2021 during the GameStop saga, when he witnessed the devastating impact of market manipulation on his clients. “When brokerages removed the buy button on GameStop, I saw millions of dollars in client nest eggs vanish because Wall Street got caught cheating,” Malone said. “That moment changed everything for me. I became a fiduciary committed to fighting market corruption.”
His alignment with Quantum BioPharma was a natural fit. “When I learned about Quantum’s mission to cure MS and their fight against stock manipulation, I knew I wanted to join their battle,” Malone added. His social media platforms, where he discusses market trends and educates followers on financial literacy, have amplified his influence, making him a powerful ally for Quantum’s cause.
Beyond his financial acumen, Malone is also a philanthropist. He has established a charitable fund aimed at integrating personal finance and financial literacy into the U.S. public education system, addressing what he sees as a critical gap in financial education.
Quantum BioPharma’s Broader Mission
Quantum BioPharma is not only focused on combating market manipulation but also on advancing its innovative biotech portfolio. The company’s lead candidate, Lucid-MS, has shown promise in preclinical models for preventing and reversing myelin degradation, a key mechanism in multiple sclerosis. Additionally, Quantum has developed unbuzzd™, a product spun out to Celly Nutrition Corp., with Quantum retaining a 25.71% stake and royalty rights.
With Malone’s appointment, Quantum BioPharma is signaling a dual commitment: to protect its shareholders from predatory market practices and to push forward its groundbreaking medical research. His social media influence and financial expertise could prove instrumental in rallying retail investors and raising awareness about the company’s goals.
A Battle Worth Fighting
As naked short selling and stock manipulation remain contentious issues in the financial world, Kevin Malone’s role at Quantum BioPharma represents a bold step toward transparency and fairness. His ability to connect with retail investors through social media, combined with his deep understanding of market dynamics, positions him as a key figure in Quantum’s fight against market corruption.
For Quantum BioPharma, this partnership is about more than just financial strategy—it’s about building a movement. As Malone puts it, “This is the kind of battle worth joining.” Investors and followers alike will be watching closely as this influencer-turned-advisor helps steer Quantum BioPharma toward a future free from manipulation and focused on transformative healthcare solutions.
For more information, visit www.quantumbiopharma.com.
Disclaimer: This article is based on the provided press release and does not constitute financial advice. Always conduct your own research before making investment decisions.
Lusso’s News LLC – General Disclaimer
General Disclosure
LussosNews.com is a financial information website that provides news, analysis, and marketing services related to publicly traded companies. By using this website, you agree to the terms and conditions outlined in this Disclaimer.
Forward-Looking Statements
This website may include forward-looking statements regarding the future anticipated plans, performance, and development of the companies we discuss. Any statements that are not historical facts should be considered forward-looking. These statements generally include words such as “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” and “intends.” Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
Informational Purposes Only; Not Investment Advice
All content on LussosNews.com, including articles, posts, newsletters, and comments, is provided solely for educational and informational purposes and should NOT be construed as a securities-related offer, solicitation, or personalized investment advice. LussosNews.com does not recommend buying, selling, or holding any security, and readers are advised to consult a licensed or registered professional before making any investment decisions. Investing in publicly traded securities, including those with low floats such as Quantum BioPharma Ltd., involves significant risk and could result in total loss of invested capital.
No Guarantees & No Liability
LussosNews.com does not guarantee the accuracy of any statements regarding Quantum BioPharma Ltd. or any other company discussed. If an individual chooses to invest in a security mentioned on LussosNews.com, they agree to hold LussosNews.com harmless and free of liability. There are no guarantees in the financial markets, and investments can experience extreme volatility or be lost entirely.
No Investment Advisor or Registered Broker
Neither LussosNews.com, nor any of its owners, employees, or affiliates, are registered as a securities broker-dealer, investment advisor (IA), or IA representative with any securities regulatory authority. LussosNews.com does not provide investment advice, and all content should be interpreted as general financial discussion and market commentary.
Risks and Warnings
Content on this website is intended for reference purposes only and does not constitute an offer or solicitation to purchase or sell any security. Readers acknowledge that they are not using LussosNews.com’s content to make investment decisions. All individuals should consult with licensed financial professionals before making any investment decisions.
OTC & Small Float Stock Risk Warnings
Securities with low public floats, such as Quantum BioPharma Ltd. (NASDAQ: QNTM), may be highly volatile. Small float stocks often experience significant price fluctuations, low liquidity, and higher risks of price manipulation. Additionally, investments in Over-the-Counter (OTC) securities or early-stage biopharmaceutical stocks can involve substantial risks, including difficulty in selling positions due to low trading volume and unpredictable price movements.
Safe Harbor Statement
Forward-looking statements published on this website are subject to risks and uncertainties that may cause actual results to differ from projections. LussosNews.com does not guarantee the accuracy of any forward-looking statements and assumes no responsibility for their interpretation or usage by readers.
Compensation Disclosure
Quantum BioPharma Ltd. has engaged owners of LussosNews.com for an Investor Awareness and Marketing Service Agreement from February 10, 2024, to May 7, 2024, with total compensation of $25,000 USD.
From time to time, LussosNews.com provides information about publicly traded companies that have retained our services for advertising, branding, marketing, analytics, and news distribution. Compensation creates an actual or potential conflict of interest, and readers should assume LussosNews.com may have a financial relationship with the companies mentioned.
We may buy or sell securities of the companies discussed at any time, potentially creating a conflict of interest. Readers should conduct their own due diligence before making any investment decisions.
Consent
By using this website, you agree to this disclaimer and acknowledge the risks associated with investing in publicly traded securities. If you do not agree with these terms, please exit the website immediately.